Hero banner - Meningococcal Meningitis

Meningococcal meningitis

Meningococcal meningitis is a rare but potentially devastating bacterial infection. The disease can kill in a matter of hours or cause severe long-term sequelae with devastating effects on the individuals and their families.
At Sanofi Pasteur, we believe in a world where no one suffers or dies from vaccine preventable diseases and that everyone should have access to the broadest protection. Building on 40 years of science-led research in meningococcal infection, we are developing new vaccines to further expand protection of individuals, from infant to older adults, worldwide.

Vidéo - Anna jour 3

World Immunization Week

Twitter cards - Meningitis - Animation
Did you know - Méningite
Video - Lily testimonial

Lily’s testimonial

Routine vaccination program - Meningitis

Routine Vaccination Programs

Despite the unpredictability and severity of the disease, given the low incidence of the disease, routine immunization programs tend to focus on the populations with higher risk of meningococcal meningitis leaving room for outbreaks in unprotected populations.
The early symptoms - Meningitis
The early symptoms of meningoccal meningitis can be misleading as they look like flu. If you suspect meningitis, seek medical attention immediately 4
40 years fighting - Meningitis

40 years fighting meningococcal meningitis

World free from meningitis by 2030

World free from meningitis by 2030

We are committed to playing our part in achieving the WHO and Meningitis Research Foundation stated vision of a world free from meningitis by 2030. 

References

  1. Meningitis Research Foundation. What are meningitis and septicaemia. Accessed March 2019. https://www.meningitis.org/meningitis/what-is-meningitis
  2. Martinón-Torres, F. Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements. Journal of Adolescent Health 59. Volume 59, Issue 1, March 2016. Pages 12-20.
  3. Ref CDC. Meningococcal disease – Diagnosis, Treatment, and Complications. Accessed March 2019. https://www.cdc.gov/meningococcal/about/diagnosis-treatment.html
  4. ECDC. Meningococcal disease: Recommended vaccinations. Accessed February 2019. https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1
  5. Australian Department for Health. National Immunisation Program schedule. Accessed March 2019. https://beta.health.gov.au/resources/publications/national-immunisation-program-schedule-landscape
  6. Arora, S. National Immunization Schedule India: A Review. Research & Reviews: A Journal of Immunology. Volume 7, Issue 3, 2017. https://www.researchgate.net/publication/323005378_National_Immunization_Schedule_India_A_Review
  7. Zheng, Y., et al. The landscape of vaccines in China: history, classification, supply, and price. BMC Infectious Diseases. Volume 18, Issue 1, 2018. Page 507. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172750/
  8. Unicef. Meningococcal Vaccines & Market Supply Update. 2015. Page 6.
  9. CDC. Meningococcal disease – Signs and Symptoms. Accessed March 2019. https://www.cdc.gov/meningococcal/about/symptoms.html

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies
OK